300122 Chongqing Zhifei Biological Products
- 34.22
- -0.24-0.70%
Chongqing Zhifei Biological Products News
Good payback? Zhifei Biotech calls on domestic nine-valent HPV vaccine manufacturers to participate in the promotion | Direct access to the performance conference
① Whether the imported MSD nine-valent HPV vaccine will be impacted by domestic brands in the future is the primary concern of investors at today's Zhifei Biotech performance conference. ② Chairman Jiang Rensheng said that the HPV vaccine market space is huge, and more manufacturers participating in the promotion will be helpful to the company. ③ Financial Director Li Zhenjing believes that the company's high accounts receivable and inventory growth in the first quarter were due to the expansion of sales and business scale.
Research Report Nuggets丨CITIC Construction Investment: Zhifei Biotech's shingles vaccine contributed new volume and maintained a “buy” rating
Gelonghui, May 9 | CITIC Construction Investment Securities Research Report indicates that the 23-year results of Zhifei Biotech (300122.SZ) are in line with expectations, and the results of the 241 quarterly report are lower than previous expectations. The results achieved rapid growth in 2023, mainly due to the rapid release of the 9-valent HPV vaccine. In 2024, the company will continue to promote the release of the HPV vaccine and increase the domestic vaccination rate. At the same time, in the first year of sales of the GSK recombinant shingles vaccine as an agent, the company will actively complete the promotion goals for the whole year, providing new impetus for performance growth. In terms of independent products, the volume of microcard and IKA products is expected to accelerate as promotion and admission gradually advance; R&D
Zhifei Biotech (300122): The existing business is steady and far reaching new contributions to the shingles vaccine
Core Thoughts On April 22, the company released the 2023 Annual Report and the 2024 First Quarter Report. The 9-valent HPV vaccine led to rapid growth in the company's annual performance and is expected to remain stable in the future. The company signed with GSK
Zhifei Biotech (300122): HPV vaccine enters steady growth period, focus on shingles vaccine dosage
The 2023 results are basically in line with our expectations. The company announced the 2023 and 1Q24 results: the company's revenue in 2023 was 52,918 billion yuan, an increase of 38.30% over the previous year, and net profit of 8.070 billion yuan.
Zhifei Biotech (300122): Performance during the reporting period was slightly lower than expected, “Self-developed & Agency” dual-drive built a long-term growth engine for performance
Event: The company released the 2023 annual report and the first quarter report of 2024. The full year of 2023 achieved operating income of 52,918 billion yuan (YoY +38.30%) and net profit of 8.070 billion yuan (Yo
Zhifei Biotech (300122): Nine valent HPV accelerates the release of shingles and opens up room for growth
Performance summary: In 2023, the company achieved operating income of $52,918 billion (+38.30%), net profit of 8.070 billion yuan (+7.04%), net profit of non-return to mother of 7.915 billion yuan (+5)
Express News | Zhifei Biotech: 26-valent pneumococcal conjugate vaccine obtained clinical trial approval notice
Zhifei Biotech (300122): HPV vaccine continuous release development pipeline enters harvest period
The company released the 2023 annual report and the 2024 quarterly report: in 2023, the company achieved revenue of $52,918 billion (+38.30%, the following are all year-on-year ratios) and net profit to mother of 8.070 billion yuan (+7.04
Zhifei Biotech (300122): Further release of the HPV vaccine, and the shingles vaccine will soon contribute new doses
Matters: (1) The company released its 2023 annual report, achieving full year revenue of 52,918 billion yuan (+38.30%) and net profit to mother of 8.070 billion yuan (+7.04%). Net profit after deducting non-return to mother was 7
Express News | The latest 10 billion private equity positions revealed! Deng Xiaofeng and Feng Liu move frequently
Zhifei Biotech (300122): Changes in agent product structure expected to release shingles vaccine
Incident: The company released the 2023 report and the 2024 quarterly report. In 2023, the company achieved revenue of 52.92 billion yuan, an increase of 38.3% over the previous year; realized net profit to mother of 8.07 billion yuan, an increase of 7% over the previous year; achieved deductions
Express News | Zhifei Biotech's affiliate simeglutide declared clinical weight loss indications
Vaccine leaders have lost 280 billion
No more highlights
Chongqing Zhifei Biological Products Co., Ltd. Just Missed EPS By 35%: Here's What Analysts Think Will Happen Next
The analysts might have been a bit too bullish on Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122), given that the company fell short of expectations when it released its quarterly results
Zhifei Biotech (300122) Annual Report Review Report: Company fundamentals, high quality growth, high certainty, and shingles are expected to create a second growth curve
The company released the 2023 Annual Report & 2024 Quarterly Report: In 2023, it achieved operating income of 52,918 billion yuan (+38.30% YoY, same below) and net profit of 8.0 billion yuan (+7.04%) to mother, deducted
Annual Report Direct | Is the HPV vaccine business not doing well? Zhifei Biotech's profitability declined
Zhifei Biotech's vaccine agency business is being tested.
Zhifei Biotech fell nearly 15%, and the company responded
Zhifei Biotech moved lower after opening low. By the close of early trading, it had fallen 14.67% to 34.31 yuan. According to the news, Zhifei Biotech's revenue for the first quarter of this year was 11.396 billion yuan, up 2% year on year; net profit to mother was 1,458 billion yuan, down 28.26% year on year. Zhifei Biotech did not explain the reason for the decline in profits in the first quarter in the announcement. In response, the reporter called Zhifei Biotech's investor hotline as an investor to inquire about the reason for the decline in performance. The relevant staff said, “Sales of the 4-valent HPV vaccine have declined relatively. The share of the 9-valent HPV vaccine has increased, and the nine-valent HPV and 4
A-share pharmaceutical stocks declined, and many stocks such as Zhifei Biotech fell by more than 10%
Gelonghui, April 23 | Zhifei Biotech, Baiyang Pharmaceutical, Tuoxin Pharmaceutical, and Baicheng Pharmaceutical all fell by more than 10%, while Anke Biotech and Tebao Biotech fell more than 8%.
A-share changes丨Zhifei Biotech plummeted nearly 13% to a new low of more than 4 years, and Q4 net profit fell 20.31% year on year
Gelonghui, April 23 | Zhifei Biotech (300122.SZ) jumped low and plummeted 12.8% to 35.06 yuan at the beginning of the session. The stock price hit a new low since January 2020. According to the financial report released by Zhifei Biotech last night, revenue in 2023 was 52,918 billion yuan, up 38.30% year on year; net profit attributable to shareholders of listed companies was 8.070 billion yuan, up 7.04% year on year; and non-net profit attributable to shareholders of listed companies was 7.915 billion yuan, up 5.40% year on year. Among them, in the fourth quarter of 2023, the main revenue for a single quarter was 13.646 billion yuan, up 30.7% year-on-year
Zhifei Biotech's product revenue share rose to 98%, and net profit declined year-on-year for two consecutive quarters|Financial Report Interpretation
① Last year, Zhifei Biotech's revenue increased by nearly 40%, but the net profit growth rate was only in single digits. 2023Q4 and 2024Q1 net profit growth rate declined year on year; ② Zhifei Biotech's overall gross margin and gross margin of agent products both declined year on year last year, and sales expenses increased by nearly a quarter.
Analysis
Price Target
No Data
